We also found amplification of the TERT (5p15.33) and CDK4 loci (12q14) in 76.5% and 82% of the tumor samples assessed, respectively; and deletions of the CDKN2A (9p21.3), RB1 (13q14) and ZNRF3 loci (22q12.1) in 35%, 59% and 76.5% of tumors, with the incidence of each higher than that previously reported [8, 16]. Here, CDK4 is linked to neoplasm.